AT

Athersys

- NASDAQ:ATHX
Last Updated 2024-04-30

Indeed Snapshot

Track Athersys reviews on Indeed to uncover insights on employee sentiment

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Profile Url Name Website Industry Description Revenue Headquarters location CEO Rating: CEO (%) Rating: CEO Responses Count Rating: Overall Happiness: Compensation score Happiness: Support score Happiness: Purpose score Happiness: Flexibility score Happiness: Energy score Happiness: Work Happiness score Happiness: Trust score Happiness: Learning score Happiness: Belonging score Happiness: Inclusion score Happiness: Overall score Happiness: Appreciation score Happiness: Achievement score Happiness: Responses Count Review Count Ratings Responses Count Rating: Culture & Values Rating: Compensation & Benefits Rating: Job Security & Advancement Rating: Senior Management Rating: Worklife Balance Interview: Duration Responses count Interview Duration Interview: Difficulty Responses count Interview Difficulty Interview: Experience Responses count Interview Experience Work Culture: Stressful (0) to Relaxed (1) Ratio Work Culture: Slow Paced (0) to Fast Paced (1) Ratio Work Culture: Competitive (0) to Collaborative (1) Ratio Date Added Date Updated Company Name Sector Industry
nasdaq:athx https://www.indeed.com/cmp/athersys,-inc. Aug 29th, 2022 12:00AM Open Athersys, Inc. Pharmaceutical & Biotechnology Athersys is a clinical-stage regenerative medicine company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our current clinical development programs are focused on treating critical care indications where the current standard of care is limited or inadequate for many patients. MultiStem® (invimestrocel), a patented and proprietary allogeneic stem cell product candidate, is the Company's lead platform and is currently in clinical development. The Company's most advanced program is focused on the treatment of ischemic stroke, which is currently being evaluated in a registrational trial in Japan and an ongoing Phase 3 clinical trial in North America under a Special Protocol Assessment and in Europe under a Final Scientific Advice positive opinion. MultiStem is also being evaluated in a pivotal Phase 2/3 study to treat acute respiratory distress syndrome (ARDS), with Fast Track and RMAT designation from the FDA and in a Phase 2 trial evaluating MultiStem for the treatment of traumatic injuries. Stroke, ARDS and trauma represent areas of clinical need for patients and substantial commercial opportunities. Our Mission: Committed to Developing Therapies to Extend and Enhance the Quality of Human Life. RRv1_5M_25M 3201 Carnegie Avenue Cleveland, OH 44115 William (B.J.) Lehmann 4.80 5.00 5.00 5.00 4.60 3.60 4.60 4.80 Aug 29th, 2022 11:27AM Aug 29th, 2022 11:27AM Athersys Health Care Equipment & Services
nasdaq:athx https://www.indeed.com/cmp/athersys,-inc. Aug 28th, 2022 12:00AM Open Athersys, Inc. Pharmaceutical & Biotechnology Athersys is a clinical-stage regenerative medicine company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our current clinical development programs are focused on treating critical care indications where the current standard of care is limited or inadequate for many patients. MultiStem® (invimestrocel), a patented and proprietary allogeneic stem cell product candidate, is the Company's lead platform and is currently in clinical development. The Company's most advanced program is focused on the treatment of ischemic stroke, which is currently being evaluated in a registrational trial in Japan and an ongoing Phase 3 clinical trial in North America under a Special Protocol Assessment and in Europe under a Final Scientific Advice positive opinion. MultiStem is also being evaluated in a pivotal Phase 2/3 study to treat acute respiratory distress syndrome (ARDS), with Fast Track and RMAT designation from the FDA and in a Phase 2 trial evaluating MultiStem for the treatment of traumatic injuries. Stroke, ARDS and trauma represent areas of clinical need for patients and substantial commercial opportunities. Our Mission: Committed to Developing Therapies to Extend and Enhance the Quality of Human Life. RRv1_5M_25M 3201 Carnegie Avenue Cleveland, OH 44115 William (B.J.) Lehmann 4.80 5.00 5.00 5.00 4.60 3.60 4.60 4.80 Aug 28th, 2022 04:27AM Aug 28th, 2022 04:27AM Athersys Health Care Equipment & Services
nasdaq:athx https://www.indeed.com/cmp/athersys,-inc. Aug 27th, 2022 12:00AM Open Athersys, Inc. Pharmaceutical & Biotechnology Athersys is a clinical-stage regenerative medicine company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our current clinical development programs are focused on treating critical care indications where the current standard of care is limited or inadequate for many patients. MultiStem® (invimestrocel), a patented and proprietary allogeneic stem cell product candidate, is the Company's lead platform and is currently in clinical development. The Company's most advanced program is focused on the treatment of ischemic stroke, which is currently being evaluated in a registrational trial in Japan and an ongoing Phase 3 clinical trial in North America under a Special Protocol Assessment and in Europe under a Final Scientific Advice positive opinion. MultiStem is also being evaluated in a pivotal Phase 2/3 study to treat acute respiratory distress syndrome (ARDS), with Fast Track and RMAT designation from the FDA and in a Phase 2 trial evaluating MultiStem for the treatment of traumatic injuries. Stroke, ARDS and trauma represent areas of clinical need for patients and substantial commercial opportunities. Our Mission: Committed to Developing Therapies to Extend and Enhance the Quality of Human Life. RRv1_5M_25M 3201 Carnegie Avenue Cleveland, OH 44115 William (B.J.) Lehmann 4.80 5.00 5.00 5.00 4.60 3.60 4.60 4.80 Aug 27th, 2022 03:46AM Aug 27th, 2022 03:46AM Athersys Health Care Equipment & Services
nasdaq:athx https://www.indeed.com/cmp/athersys,-inc. Aug 25th, 2022 12:00AM Open Athersys, Inc. Pharmaceutical & Biotechnology Athersys is a clinical-stage regenerative medicine company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our current clinical development programs are focused on treating critical care indications where the current standard of care is limited or inadequate for many patients. MultiStem® (invimestrocel), a patented and proprietary allogeneic stem cell product candidate, is the Company's lead platform and is currently in clinical development. The Company's most advanced program is focused on the treatment of ischemic stroke, which is currently being evaluated in a registrational trial in Japan and an ongoing Phase 3 clinical trial in North America under a Special Protocol Assessment and in Europe under a Final Scientific Advice positive opinion. MultiStem is also being evaluated in a pivotal Phase 2/3 study to treat acute respiratory distress syndrome (ARDS), with Fast Track and RMAT designation from the FDA and in a Phase 2 trial evaluating MultiStem for the treatment of traumatic injuries. Stroke, ARDS and trauma represent areas of clinical need for patients and substantial commercial opportunities. Our Mission: Committed to Developing Therapies to Extend and Enhance the Quality of Human Life. RRv1_5M_25M 3201 Carnegie Avenue Cleveland, OH 44115 William (B.J.) Lehmann 4.80 5.00 5.00 5.00 4.60 3.60 4.60 4.80 Aug 25th, 2022 08:26AM Aug 25th, 2022 08:26AM Athersys Health Care Equipment & Services
nasdaq:athx https://www.indeed.com/cmp/athersys,-inc. Aug 23rd, 2022 12:00AM Open Athersys, Inc. Pharmaceutical & Biotechnology Athersys is a clinical-stage regenerative medicine company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our current clinical development programs are focused on treating critical care indications where the current standard of care is limited or inadequate for many patients. MultiStem® (invimestrocel), a patented and proprietary allogeneic stem cell product candidate, is the Company's lead platform and is currently in clinical development. The Company's most advanced program is focused on the treatment of ischemic stroke, which is currently being evaluated in a registrational trial in Japan and an ongoing Phase 3 clinical trial in North America under a Special Protocol Assessment and in Europe under a Final Scientific Advice positive opinion. MultiStem is also being evaluated in a pivotal Phase 2/3 study to treat acute respiratory distress syndrome (ARDS), with Fast Track and RMAT designation from the FDA and in a Phase 2 trial evaluating MultiStem for the treatment of traumatic injuries. Stroke, ARDS and trauma represent areas of clinical need for patients and substantial commercial opportunities. Our Mission: Committed to Developing Therapies to Extend and Enhance the Quality of Human Life. RRv1_5M_25M 3201 Carnegie Avenue Cleveland, OH 44115 William (B.J.) Lehmann 4.80 5.00 5.00 5.00 4.60 3.60 4.60 4.80 Aug 23rd, 2022 10:20AM Aug 23rd, 2022 10:20AM Athersys Health Care Equipment & Services
nasdaq:athx https://www.indeed.com/cmp/athersys,-inc. Aug 21st, 2022 12:00AM Open Athersys, Inc. Pharmaceutical & Biotechnology Athersys is a clinical-stage regenerative medicine company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our current clinical development programs are focused on treating critical care indications where the current standard of care is limited or inadequate for many patients. MultiStem® (invimestrocel), a patented and proprietary allogeneic stem cell product candidate, is the Company's lead platform and is currently in clinical development. The Company's most advanced program is focused on the treatment of ischemic stroke, which is currently being evaluated in a registrational trial in Japan and an ongoing Phase 3 clinical trial in North America under a Special Protocol Assessment and in Europe under a Final Scientific Advice positive opinion. MultiStem is also being evaluated in a pivotal Phase 2/3 study to treat acute respiratory distress syndrome (ARDS), with Fast Track and RMAT designation from the FDA and in a Phase 2 trial evaluating MultiStem for the treatment of traumatic injuries. Stroke, ARDS and trauma represent areas of clinical need for patients and substantial commercial opportunities. Our Mission: Committed to Developing Therapies to Extend and Enhance the Quality of Human Life. RRv1_5M_25M 3201 Carnegie Avenue Cleveland, OH 44115 William (B.J.) Lehmann 4.80 5.00 5.00 5.00 4.60 3.60 4.60 4.80 Aug 21st, 2022 12:03PM Aug 21st, 2022 12:03PM Athersys Health Care Equipment & Services
nasdaq:athx https://www.indeed.com/cmp/athersys,-inc. Aug 20th, 2022 12:00AM Open Athersys, Inc. Pharmaceutical & Biotechnology Athersys is a clinical-stage regenerative medicine company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our current clinical development programs are focused on treating critical care indications where the current standard of care is limited or inadequate for many patients. MultiStem® (invimestrocel), a patented and proprietary allogeneic stem cell product candidate, is the Company's lead platform and is currently in clinical development. The Company's most advanced program is focused on the treatment of ischemic stroke, which is currently being evaluated in a registrational trial in Japan and an ongoing Phase 3 clinical trial in North America under a Special Protocol Assessment and in Europe under a Final Scientific Advice positive opinion. MultiStem is also being evaluated in a pivotal Phase 2/3 study to treat acute respiratory distress syndrome (ARDS), with Fast Track and RMAT designation from the FDA and in a Phase 2 trial evaluating MultiStem for the treatment of traumatic injuries. Stroke, ARDS and trauma represent areas of clinical need for patients and substantial commercial opportunities. Our Mission: Committed to Developing Therapies to Extend and Enhance the Quality of Human Life. RRv1_5M_25M 3201 Carnegie Avenue Cleveland, OH 44115 William (B.J.) Lehmann 4.80 5.00 5.00 5.00 4.60 3.60 4.60 4.80 Aug 20th, 2022 01:40PM Aug 20th, 2022 01:40PM Athersys Health Care Equipment & Services
nasdaq:athx https://www.indeed.com/cmp/athersys,-inc. Aug 19th, 2022 12:00AM Open Athersys, Inc. Pharmaceutical & Biotechnology Athersys is a clinical-stage regenerative medicine company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our current clinical development programs are focused on treating critical care indications where the current standard of care is limited or inadequate for many patients. MultiStem® (invimestrocel), a patented and proprietary allogeneic stem cell product candidate, is the Company's lead platform and is currently in clinical development. The Company's most advanced program is focused on the treatment of ischemic stroke, which is currently being evaluated in a registrational trial in Japan and an ongoing Phase 3 clinical trial in North America under a Special Protocol Assessment and in Europe under a Final Scientific Advice positive opinion. MultiStem is also being evaluated in a pivotal Phase 2/3 study to treat acute respiratory distress syndrome (ARDS), with Fast Track and RMAT designation from the FDA and in a Phase 2 trial evaluating MultiStem for the treatment of traumatic injuries. Stroke, ARDS and trauma represent areas of clinical need for patients and substantial commercial opportunities. Our Mission: Committed to Developing Therapies to Extend and Enhance the Quality of Human Life. RRv1_5M_25M 3201 Carnegie Avenue Cleveland, OH 44115 William (B.J.) Lehmann 4.80 5.00 5.00 5.00 4.60 3.60 4.60 4.80 Aug 19th, 2022 12:03PM Aug 19th, 2022 12:03PM Athersys Health Care Equipment & Services
nasdaq:athx https://www.indeed.com/cmp/athersys,-inc. Aug 18th, 2022 12:00AM Open Athersys, Inc. Pharmaceutical & Biotechnology Athersys is a clinical-stage regenerative medicine company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our current clinical development programs are focused on treating critical care indications where the current standard of care is limited or inadequate for many patients. MultiStem® (invimestrocel), a patented and proprietary allogeneic stem cell product candidate, is the Company's lead platform and is currently in clinical development. The Company's most advanced program is focused on the treatment of ischemic stroke, which is currently being evaluated in a registrational trial in Japan and an ongoing Phase 3 clinical trial in North America under a Special Protocol Assessment and in Europe under a Final Scientific Advice positive opinion. MultiStem is also being evaluated in a pivotal Phase 2/3 study to treat acute respiratory distress syndrome (ARDS), with Fast Track and RMAT designation from the FDA and in a Phase 2 trial evaluating MultiStem for the treatment of traumatic injuries. Stroke, ARDS and trauma represent areas of clinical need for patients and substantial commercial opportunities. Our Mission: Committed to Developing Therapies to Extend and Enhance the Quality of Human Life. RRv1_5M_25M 3201 Carnegie Avenue Cleveland, OH 44115 William (B.J.) Lehmann 4.80 5.00 5.00 5.00 4.60 3.60 4.60 4.80 Aug 18th, 2022 03:47AM Aug 18th, 2022 03:47AM Athersys Health Care Equipment & Services
nasdaq:athx https://www.indeed.com/cmp/athersys,-inc. Aug 17th, 2022 12:00AM Open Athersys, Inc. Pharmaceutical & Biotechnology Athersys is a clinical-stage regenerative medicine company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our current clinical development programs are focused on treating critical care indications where the current standard of care is limited or inadequate for many patients. MultiStem® (invimestrocel), a patented and proprietary allogeneic stem cell product candidate, is the Company's lead platform and is currently in clinical development. The Company's most advanced program is focused on the treatment of ischemic stroke, which is currently being evaluated in a registrational trial in Japan and an ongoing Phase 3 clinical trial in North America under a Special Protocol Assessment and in Europe under a Final Scientific Advice positive opinion. MultiStem is also being evaluated in a pivotal Phase 2/3 study to treat acute respiratory distress syndrome (ARDS), with Fast Track and RMAT designation from the FDA and in a Phase 2 trial evaluating MultiStem for the treatment of traumatic injuries. Stroke, ARDS and trauma represent areas of clinical need for patients and substantial commercial opportunities. Our Mission: Committed to Developing Therapies to Extend and Enhance the Quality of Human Life. RRv1_5M_25M 3201 Carnegie Avenue Cleveland, OH 44115 William (B.J.) Lehmann 4.80 5.00 5.00 5.00 4.60 3.60 4.60 4.80 Aug 17th, 2022 09:25AM Aug 17th, 2022 09:25AM Athersys Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.